Table 3

Outcomes

OutcomeNo beta-blocker
n = 717
Beta-blocker
n = 719
Hazard ratio
(95% CI)
P-value
New AMI or all-cause mortality51 (7.1%)59 (8.2%)1.07 (0.73, 1.57)0.7
New AMI29 (4.0%)33 (4.6%)1.04 (0.63, 1.72)0.9
All-cause mortality24 (3.3%)30 (4.2%)1.13 (0.66, 1.95)0.7
Readmission due to heart failure7 (1.0%)5 (0.7%)
Readmission due to atrial fibrillation6 (0.8%)4 (0.6%)
OutcomeNo beta-blocker
n = 717
Beta-blocker
n = 719
Hazard ratio
(95% CI)
P-value
New AMI or all-cause mortality51 (7.1%)59 (8.2%)1.07 (0.73, 1.57)0.7
New AMI29 (4.0%)33 (4.6%)1.04 (0.63, 1.72)0.9
All-cause mortality24 (3.3%)30 (4.2%)1.13 (0.66, 1.95)0.7
Readmission due to heart failure7 (1.0%)5 (0.7%)
Readmission due to atrial fibrillation6 (0.8%)4 (0.6%)

Values are n (%).

The P-values are derived from a χ2 test, a Wilcoxon rank sum test and Fisher’s exact test in that order.

Hazard ratios are derived from Cox regression models, adjusted for: age, sex, diabetes, previous AMI, and multi-vessel disease.

AMI, acute myocardial infarction.

Table 3

Outcomes

OutcomeNo beta-blocker
n = 717
Beta-blocker
n = 719
Hazard ratio
(95% CI)
P-value
New AMI or all-cause mortality51 (7.1%)59 (8.2%)1.07 (0.73, 1.57)0.7
New AMI29 (4.0%)33 (4.6%)1.04 (0.63, 1.72)0.9
All-cause mortality24 (3.3%)30 (4.2%)1.13 (0.66, 1.95)0.7
Readmission due to heart failure7 (1.0%)5 (0.7%)
Readmission due to atrial fibrillation6 (0.8%)4 (0.6%)
OutcomeNo beta-blocker
n = 717
Beta-blocker
n = 719
Hazard ratio
(95% CI)
P-value
New AMI or all-cause mortality51 (7.1%)59 (8.2%)1.07 (0.73, 1.57)0.7
New AMI29 (4.0%)33 (4.6%)1.04 (0.63, 1.72)0.9
All-cause mortality24 (3.3%)30 (4.2%)1.13 (0.66, 1.95)0.7
Readmission due to heart failure7 (1.0%)5 (0.7%)
Readmission due to atrial fibrillation6 (0.8%)4 (0.6%)

Values are n (%).

The P-values are derived from a χ2 test, a Wilcoxon rank sum test and Fisher’s exact test in that order.

Hazard ratios are derived from Cox regression models, adjusted for: age, sex, diabetes, previous AMI, and multi-vessel disease.

AMI, acute myocardial infarction.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close